Atea Pharmaceuticals
AVIR
119 hedge funds and large institutions have $171M invested in Atea Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 44 increasing their positions, 42 reducing their positions, and 20 closing their positions.
233% more call options, than puts
Call options by funds: $260K | Put options by funds: $78K
5% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 42
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.23% less ownership
Funds ownership: 68.4% → 68.17% (-0.23%)
11% less funds holding
Funds holding: 133 → 119 (-14)
20% less capital invested
Capital invested by funds: $213M → $171M (-$42.7M)
70% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$8.72M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.29M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.95M |
| 4 |
BlackRock
New York
|
+$1.64M |
| 5 |
NM
Newtyn Management
New York
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.96M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.79M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.05M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$761K |
| 5 |
Morgan Stanley
New York
|
-$559K |
AVIR Hedge Fund Activity: Q3 2023 in Review
119 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q3 2023, worth a combined $171M — down 20% from $213M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of AVIR and 6 opened new positions — a net loss of 14 holders — while 42 trimmed existing stakes and 44 added.
The largest buyer was BML Capital Management, adding an estimated $8.72M. The largest seller was Fidelity Investments, cutting an estimated $6.96M.
- 119 institutional investors held Atea Pharmaceuticals (AVIR) as of Q3 2023, down from 133 in Q2 2023.
- Funds reported $171M of Atea Pharmaceuticals stock for Q3 2023, down 20% quarter-over-quarter.
- 6 funds opened new Atea Pharmaceuticals positions in Q3 2023 and 20 closed out, a net change of -14 holders.
- The largest Atea Pharmaceuticals buyer in Q3 2023 was BML Capital Management, an estimated $8.72M added.
- The largest Atea Pharmaceuticals seller in Q3 2023 was Fidelity Investments, an estimated $6.96M sold.
Based on aggregated 13F filings for Q3 2023.